Turning the clock ahead: Potential preclinical and clinical neuropharmacological targets for alcohol dependence

Current Pharmaceutical Design

Volumn 16, Issue 19, 2010, Pages 2159-2181

  Leggio, Lorenzo ^a,b   Cardone, Silvia ^b   Ferrulli, Anna ^b   Kenna, George A ^a   Diana, Marco ^c   Swift, Robert M ^a,d   Addolorato, Giovanni ^b  

^a BROWN UNIVERSITY   (United States)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF SASSARI   (Italy)

^d PROVIDENCE VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Alcohol dependence; Neurobiology; Pharmacotherapy

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; ACETALDEHYDE; ALPHA ADRENERGIC RECEPTOR; AMPA RECEPTOR; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR; CORTICOTROPIN RELEASING FACTOR; DRUGS USED IN THE TREATMENT OF ADDICTION; ENDOCANNABINOID; ETIRACETAM; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTAMATE RECEPTOR; GLUTAMATE RECEPTOR ANTAGONIST; GLUTAMIC ACID; GLYCINE REUPTAKE INHIBITOR; KAINIC ACID RECEPTOR; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROKININ 1 RECEPTOR; NEUROPEPTIDE S; NEUROPEPTIDE Y; NEUROTRANSMITTER; NEUROTRANSMITTER RECEPTOR; NICOTINIC RECEPTOR; NOCICEPTIN; ORG 25935; RIMONABANT; SUBSTANCE P; UNCLASSIFIED DRUG; VARENICLINE; YOHIMBINE;

ALCOHOLISM; ALZHEIMER DISEASE; AMNESIA; CLINICAL TRIAL; DISORIENTATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG TARGETING; DRUG TRANSPORT; DRUG TREATMENT FAILURE; HUMAN; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; PSYCHOSIS; REVIEW; SIGNAL TRANSDUCTION; STEROIDOGENESIS; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG SCREENING; PATHOPHYSIOLOGY;

ALCOHOL DETERRENTS; ALCOHOLISM; ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS;

EID: 77955632266     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210791516369     Document Type: Review

References (364)

1. Spanagel R. Alcoholism: a systems approach from molecular physiology to addictive behaviour. Physiol Rev 2009; 89: 649-705.
2. Boileau I, Assaad JM, Pihl RO, et al. Alcohol promotes dopamine release in the human nucleus accumbens. Synapse 2003; 49(4): 226-31.
3. Diana M, Pistis M, Carboni S, et al. Profound decrement of mesolimbic dopaminergic neuronal activity during ethanol withdrawal syndrome in rats: electrophysiological and biochemical evidence. Proc Natl Acad Sci USA 1993; 90(17): 7966-9.
4. Diana M, Pistis M, Muntoni A, et al. Mesolimbic dopaminergic reduction outlasts ethanol withdrawal syndrome: evidence of protracted abstinence. Neuroscience 1996; 71(2): 411-5.
5. Weiss M, Schneider EM, Tarnow J, et al. Is inhibition of oxygen radical production of neutrophils by sympathomimetics mediated via beta-2 adrenoceptors? J Pharmacol Exp Ther 1996; 278(3): 1105-13.
6. Martinez D, Kim JH, Krystal J, et al. Imaging the neurochemistry of alcohol and substance abuse. Neuroimaging Clin N Am 2007; 17(4): 539-55.
7. Volkow ND, Wang GJ, Telang F, et al. Profound decreases in dopamine release in striatum in detoxified alcoholics: possible orbitofrontal involvement. J Neurosci 2007; 27(46): 12700-6.
8. Vengeliene V, Bilbao A, Molander A, et al. Neuropharmacology of alcohol addiction. Br J Pharmacol 2008; 154(2): 299-315.
9. Bouza C, Angeles M, Muñoz A, et al. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction 2004; 99(7): 811-28.
10. Krampe H, Ehrenreich H. Supervised disulfiram as adjunct to psychotherapy in alcoholism treatment. Curr Pharm Des 2010; 19: 2076-90.
11. Garbutt JC. Efficacy and tolerability of naltrexone in the management of alcohol dependence. Curr Pharm Des 2010; 19: 2091-7.
12. Kiefer F, Mann K. Acamprosate: how, where, and for whom does it work? Mechanism of action, treatment targets, and individualized therapy. Curr Pharm Des 2010; 19: 2098-102.
13. Johnson BA, Ait-Daoud N. Topiramate in the new generation of drugs: efficacy in the treatment of alcoholic patients. Curr Pharm Des 2010; 19: 2103-12.
14. Kenna GA. Medications acting on the serotonergic system in the treatment of alcoholic patients. Curr Pharm Des 2010; 19: 2126-35.
15. Addolorato G, Leggio L. Safety and efficacy of baclofen in the treatment of alcohol-dependent patients. Curr Pharm Des 2010; 19: 2113-17.
16. Swift RM. Medications acting on the dopaminergic system in the treatment of alcoholic patients. Curr Pharm Des 2010; 19: 2136-40.
17. Fattore L, Fadda P, Fratta W. Endocannabinoid regulation of relapse mechanisms. Pharmacol Res 2007; 56(5): 418-27.
18. Hungund BL, Basavarajappa BS. Role of endocannabinoids and cannabinoid CB1 receptors in alcohol-related behaviors. Ann N Y Acad Sci 2004; 1025: 515-27.
19. Malinen H, Hyytiä P. Ethanol self-administration is regulated by CB1 receptors in the nucleus accumbens and ventral tegmental area in alcohol-preferring AA rats. Alcohol Clin Exp Res 2008; 32(11): 1976-83.
20. Heilig M, Egli M. Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. Pharmacol Ther 2006; 111(3): 855-76.
21. Basavarajappa BS, Cooper TB, Hungund BL. Chronic ethanol administration down-regulates cannabinoid receptors in mouse brain synaptic plasma membrane. Brain Res 1998; 793(1-2): 212-8.
22. Basavarajappa BS, Hungund BL. Down-regulation of cannabinoid receptor agonist-stimulated [35S]GTP gamma S binding in synaptic plasma membrane from chronic ethanol exposed mouse. Brain Res1999; 815(1): 89-97.
23. Basavarajappa BS. The endocannabinoid signaling system: a potential target for next-generation therapeutics for alcoholism. Mini Rev Med Chem 2007; 7(8): 769-79.
24. Colombo G, Serra S, Brunetti G, et al. Stimulation of voluntary ethanol intake by cannabinoid receptor agonists in ethanol-preferring sP rats. Psychopharmacology (Berl) 2002; 159(2): 181-7.
25. Hungund BL, Szakall I, Adam A, et al. Cannabinoid CB1 receptor knockout mice exhibit markedly reduced voluntary alcohol consumption and lack alcohol-induced dopamine release in the nucleus accumbens. J Neurochem 2003; 84(4): 698-704.
26. Naassila M, Pierrefiche O, Ledent C, et al. Decreased alcohol selfadministration and increased alcohol sensitivity and withdrawal in CB1 receptor knockout mice. Neuropharmacology 2004; 46(2): 243-53.
27. Poncelet M, Maruani J, Calassi R, et al. Overeating, alcohol and sucrose consumption decrease in CB1 receptor deleted mice. Neurosci Lett 2003; 343(3): 216-8.
28. Thanos PK, Dimitrakakis ES, Rice O, et al. Ethanol selfadministration and ethanol conditioned place preference are reduced in mice lacking cannabinoid CB1 receptors. Behav Brain Res 2005; 164(2): 206-13.
29. Malinen H, Hyytiä P. Ethanol self-administration is regulated by CB1 receptors in the nucleus accumbens and ventral tegmental area in alcohol-preferring AA rats. Alcohol Clin Exp Res 2008; 32(11): 1976-83.
30. Rinaldi-Carmona M, Barth F, Héaulme M, et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994; 350: 240-4.
31. Serra S, Carai MA, Brunetti G, et al. The cannabinoid receptor antagonist SR 141716 prevents acquisition of drinking behavior in alcohol-preferring rats. Eur J Pharmacol 2001; 430(2-3): 369-71.
32. Bell RL, Rodd ZA, Sable HJK, et al. Cannabinoid CB1 antagonist reduces alcohol intake during acquisition, maintenance, and relapse in inbred alcohol preferring (IP) rats. Abstract Viewer/Itinerary Planner. Washington DC: Society for Neuroscience 2004; Program No. 489.6.
33. Poncelet M, Maruani J, Calassi R, et al. Overeating, alcohol and sucrose consumption decrease in CB1 receptor deleted mice. Neurosci Lett 2003; 343(3): 216-8.
34. Lallemand F, Soubrié PH, De Witte PH. Effects of CB1 cannabinoid receptor blockade on ethanol preference after chronic ethanol administration. Alcohol Clin Exp Res 2001; 25(9): 1317-23.
35. Colombo G, Agabio R, Fà M, et al. Reduction of voluntary ethanol intake in ethanol-preferring sP rats by the cannabinoid antagonist SR-141716. Alcohol Alcohol 1998; 33(2): 126-30.
36. Colombo G, Orrù A, Lai P, et al. The cannabinoid CB1 receptor antagonist, rimonabant, as a promising pharmacotherapy for alcohol dependence: preclinical evidence. Mol Neurobiol 2007; 36(1): 102-12.
37. Dyr W, Ligieza J, Kostowski W. The effect of cannabinoid CB(1) receptor antagonist rimonabant (SR-141716) on ethanol drinking in high-preferring rats. Alcohol 2008; 42(6): 509-12.
38. Lallemand F, Soubrié P, De Witte P. Effects of CB1 cannabinoid receptor blockade on ethanol preference after chronic alcohol administration combined with repeated re-exposures and withdrawals. Alcohol Alcohol 2004; 39(6): 486-92.
39. Freedland CS, Sharpe AL, Samson HH, et al. Effects of SR141716A on ethanol and sucrose self-administration. Alcohol Clin Exp Res 2001; 25(2): 277-82.
40. Hansson AC, Bermúdez-Silva FJ, Malinen H, et al. Genetic impairment of frontocortical endocannabinoid degradation and high alcohol preference. Neuropsychopharmacology 2007; 32(1): 117- 26.
41. Rodd ZA, Bell RL, Pommer TJ, et al. The CB1 antagonist SR141716 transiently reduces operant ethanol selfadministration during relapse and maintenance, and inhibits alcohol seeking in alcohol- preferring (P) rats. Alcohol Clin Exp Res 2005; 29: 19A.
42. Roberto M, Cruz M, Bajo M, et al. The Endocannabinoid System Tonically Regulates Inhibitory Transmission and Depresses the Effect of Ethanol in Central Amygdala. Neuropsychopharmacology 2010 May 12. [Epub ahead of print]
43. Serra S, Brunetti G, Pani M, et al. Blockade by the cannabinoid CB(1) receptor antagonist, SR 141716, of alcohol deprivation effect in alcoholpreferring rats. Eur J Pharmacol 2002; 443: 95-7.
44. Cippitelli A, Bilbao A, Hansson AC, et al. Cannabinoid CB1 receptor antagonism reduces conditioned reinstatement of ethanolseeking behaviour in rats. Eur J Neurosci 2005; 21: 2243-51.
45. Parsons LH. Evidence for an endocannabinoid influence in the regulation of ethanol self-administration. Alcohol Clin Exp Res 2005; 29: 12
46. Economidou D, Mattioli L, Cifani C, et al. Effect of the cannabinoid CB1 receptor antagonist SR-141716A on ethanol selfadministration and ethanol-seeking behaviour in rats. Psychopharmacology (Berl) 2006; 183: 394-403.
47. Rinaldi-Carmona M, Barth F, Congy C, et al. SR147778 [5-(4- bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)- 1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization. J Pharmacol Exp Ther 2004; 310: 905-14.
48. Gessa GL, Serra S, Vacca G, et al. Suppressing effect of the cannabinoid CB1 receptor antagonist, SR147778, on alcohol intake and motivational properties of alcohol in alcohol-preferring sP rats. Alcohol Alcohol 2005; 40: 46-53.
49. Soyka M, Koller G, Schmidt P, et al. Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: results from a placebo-controlled, double-blind trial. J Clin Psychopharmacol 2008; 28(3): 317-24.
50. George DT, Herion DW, Jones CL, et al. Rimonabant (SR141716) has no effect on alcohol selfadministration or endocrine measures in nontreatment-seeking heavy alcohol drinkers. Psychopharmacology 2009, in press.
51. Swift RM, Leggio L. Adjunctive Pharmacotherapy in the Treatment of Alcohol and Drug Dependence. In: Peter M, Ed. Evidence-Based Addiction Treatment. USA: Elsevier 2009; pp. 287-310.
52. Abraham WC. Metaplasticity: tuning synapses and networks for plasticity. Nat Rev Neurosci 2008; 9: 387-99.
53. Parsons CG, Danysz W, Zieglgänsberger W. Excitatory amino acid neurotransmission. Handb Exp Pharmacol 2005; (169): 249-303.
54. Olive MF. Metabotropic glutamate receptor ligands as potential therapeutics for addiction. Curr Drug Abuse Rev 2009; 2(1): 83- 989.
55. Gass JT, Olive MF. Transcriptional profiling of the rat frontal cortex following administration of the mGlu5 receptor antagonists MPEP and MTEP. Eur J Pharmacol 2008; 584(2-3): 253-62.
56. Vosler PS, Bombace JC, Kosten TA. A discriminative two-lever test of dizocilpine's ability to reinstate ethanol-seeking behavior. Life Sci 2001; 69(5): 591-8.
57. Vosburg SK, Hart CL, Haney M, et al. An evaluation of the reinforcing effects of memantine in cocaine-dependent humans. Drug Alcohol Depend 2005; 79(2): 257-60.
58. Bisaga A, Evans SM. Acute effects of memantine in combination with alcohol in moderate drinkers. Psychopharmacology 2004; 172: 16-24.
59. Krupitsky EM, Neznanova O, Masalov D, et al. Effect of memantine on cue-induced alcohol craving in recovering alcoholdependent patients. Am J Psychiatry 2007; 164: 519-23.
60. Krupitsky EM, Rudenko AA, Burakov AM, et al. Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam. Alcohol Clin Exp Res 2007; 31: 604-11.
61. Evans SM, Levin FR, Brooks DJ, et al. A pilot double-blind treatment trial of memantine for alcohol dependence. Alcohol Clin Exp Res 2007; 31: 775-82.
62. Sanchis-Segura C, Borchardt T, Vengeliene V, et al. Involvement of the AMPA receptor GluR-C subunit in alcohol-seeking behaviour and relapse. J Neurosci 2006; 26: 1231-8.
63. Krebs M, Leopold K, Richter C, et al. Levetiracetam for the treatment of alcohol withdrawal syndrome: an open-label pilot trial. J Clin Psychopharmacol 2006; 26: 347-9.
64. Sarid-Segal O, Piechniczek-Buczek J, Knapp C, et al. The effects of levetiracetam on alcohol consumption in alcohol-dependent subjects: an open label study. Am J Drug Alcohol Abuse 2008; 34(4): 441-7.
65. Dhami GK, Ferguson SS. Regulation of metabotropic glutamate receptor signaling, desensitization and endocytosis. Pharmacol Ther 2006; 111(1): 260-71.
66. Pisani A, Calabresi P, Centonze D, et al. Enhancement of NMDA responses by group I metabotropic glutamate receptor activation in striatal neurones. Br J Pharmacol 1997; 120(6): 1007-14.
67. Spanagel R, Bienkowski P. Glutamatergic mechanisms in alcohol dependence and addiction. In: Lodge D, Danysz W, Parsons CG, Eds. Therapeutic Potential of Ionotropic Glutamate Receptor Antagonists and Modulators. Johnson City, TN, USA: Graham Publishing Co. 2002; pp. 375-403.
68. Gasparini F, Lingenhöhl K, Stoehr N, et al. 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology 1999; 38(10): 1493-503.
69. Carroll FI. Antagonists at metabotropic glutamate receptor subtype 5: structure activity relationships and therapeutic potential for addiction. Ann N Y Acad Sci 2008; 1141: 221-32.
70. Bäckström P, Bachteler D, Koch S, et al. mGluR5 antagonist MPEP reduces ethanol-seeking and relapse behaviour. Neuropsychopharmacology 2004; 29(5): 921-8.
71. Besheer J, Stevenson RA, Hodge CW. mGlu5 receptors are involved in the discriminative stimulus effects of self-administered ethanol in rats. Eur J Pharmacol 2006; 551: 71-5.
72. Cosford ND, Tehrani L, Roppe J, et al. 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. J Med Chem 2003; 46(2): 204-6.
73. Cowen MS, Adams C, Kraehenbuehl T, et al. The acute anticraving effect of acamprosate in alcohol-preferring rats is associated with modulation of the mesolimbic dopamine system. Addict Biol 2005; 10: 233-42.
74. Cowen MS, Krstew E, Lawrence AJ. Assessing appetitive and consummatory phases of ethanol self-administration in C57BL/6J mice under operant conditions: regulation by mGlu5 receptor antagonism. Psychopharmacology (Berl) 2007; 190(1): 21-9.
75. Besheer J, Grondin JJ, Salling MC, et al. Interoceptive effects of alcohol require mGlu5 receptor activity in the nucleus accumbens. J Neurosci 2009; 29: 9582-91.
76. Bäckström P, Hyytiä P. Suppression of alcohol self-administration and cue-induced reinstatement of alcohol seeking by the mGlu2/3 receptor agonist LY379268 and the mGlu8 receptor agonist (S)- 3,4-DCPG. Eur J Pharmacol 2005; 528(1-3): 110-8.
77. Rodd ZA, McKinzie DL, Bell RL, et al. The metabotrobic glutamate 2/3 receptor agonist LY404039 reduces alcohol-seeking but not alcohol self-administration in alcohol-preferring (P) rats. Brain Res 2006; 171: 207-15.
78. Zhao Y, Dayas CV, Aujla H, et al. Activation of group II metabotropic glutamate receptors attenuates both stress and cueinduced ethanol-seeking and modulates c-fos expression in the hippocampus and amygdala. J Neurosci 2006; 26(39): 9967-74.
79. Camron OG. Anxious-depressive comorbidity: effects on HPA axis and CNS noradrenergicfunction. Essent Psychopharmocol 2006; 7: 24-34.
80. Abelson JL, Liberzon I, Young EA, et al. Cognitive modulation of the endocrine stress response to a pharmacological challenge in normal and panic disorder subjects. Arch Gen Psychiatry 2005; 62: 668-75.
81. Sinha R. How does stress increase risk of drug abuse and relapse? Psychophamacology 2001; 158: 343-59.
82. Clarke TK, Schumann G. Gene-environment interactions resulting in risk alcohol drinking behaviour are mediated by CRF and CRF1. Pharmacol Biochem Behav 2009; 93(3): 230-6.
83. Gray TS, Bingaman EW. The amygdala: corticotropin-releasing factor, steroids, and stress. Crit Rev Neurobiol 1996; 10(2): 155-68.
84. Tsigos C, Chrousos GP. Physiology of the hypothalamic-pituitaryadrenal axis in health and dysregulation in psychiatric and autoimmune disorders. Endocrinol Metab Clin North Am 1994; 23: 451- 66.
85. Merlo Pich E, Lorang M, Yeganeh M, et al. Increase of extracellular corticotropin-releasing factor-like immunoreactivity levels in the amygdala of awake rats during restraint stress and ethanol withdrawal as measured by microdialysis. J Neurosci 1995; 15(8): 5439-47.
86. Olive MF, Koenig HN, Nannini MA, et al. Elevated extracellular CRF levels in the bed nucleus of the stria terminalis during ethanol withdrawal and reduction by subsequent ethanol intake. Pharmacol Biochem Behav 2002; 72(1-2): 213-20.
87. Baldwin HA, Rassnick S, Rivier J, et al. CRF antagonist reverses the "anxiogenic" response to ethanol withdrawal in the rat. Psychopharmacology (Berl) 1991; 103(2): 227 32.
88. Lovenberg TW, Liaw CW, Grigoriadis DE, et al. Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc Natl Acad Sci USA 1995; 92(3): 836-40.
89. Van Pett K, Viau V, Bittencourt JC, et al. Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. J Comp Neurol 2000; 428(2): 191-212.
90. Stenzel-Poore MP, Cameron VA, Vaughan J, et al. Development of Cushing's syndrome in corticotropin-releasing factor transgenic mice. Endocrinology 1992; 130: 3378-86.
91. Smith GW, Aubry JM, Dellu F, et al. Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 1998; 20(6): 1093-102.
92. Takahashi LK, Ho SP, Livanov V, et al. Antagonism of CRF(2) receptors produces anxiolytic behaviour in animal models of anxiety. Brain Res 2001; 902: 135-42.
93. Bale TL, Contarino A, Smith GW, et al. Mice deficient for corticotropin- releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nat Genet 2000; 24(4): 410-4.
94. Hansson AC, Cippitelli A, Sommer WH, et al. Variation at the rat Crhr1 locus and sensitivity to relapse into alcohol seeking induced by environmental stress. Proc Natl Acad Sci USA 2006; 103(41): 15236-41.
95. Hansson AC, Cippitelli A, Sommer WH, et al. Region-specific down-regulation of Crhr1 gene expression in alcohol-preferring msP rats following ad lib access to alcohol. Addict Biol 2007; 12(1): 30-4.
96. Sommer WH, Rimondini R, Hansson AC, et al. Upregulation of voluntary alcohol intake, behavioural sensitivity to stress, and amygdala crhr1 expression following a history of dependence. Biol Psychiatry 2008; 63(2): 139-45.
97. Treutlein J, Kissling C, Frank J, et al. Genetic association of the human corticotrophin releasing hormone receptor 1 (CRHR1) with binge drinking and alcohol intake patterns in two independent samples. Mol Psychiatry 2006; 11(6): 594-602.
98. Blomeyer D, Treutlein J, Esser G, et al. Interaction between CRHR1 gene and stressful life events predicts adolescent heavy alcohol use. Biol Psychiatry 2008; 63(2): 146-51.
99. Chu K, Koob GF, Cole M, et al. Dependence-induced increases in ethanol self-administration in mice are blocked by the CRF1 receptor antagonist antalarmin and by CRF1 receptor knockout. Pharmacol Biochem Behav 2007; 86(4): 813-21.
100. Funk CK, Zorrilla EP, Lee MJ, et al. Corticotropin-Releasing Factor 1 Antagonists Selectively Reduce Ethanol Self-Administration in Ethanol-Dependent Rats. Biol Psychiatry 2007; 61(1): 78-86.
101. Gilpin NW, Richardson HN, Koob GF. Effects of CRF1-receptor and opioid-receptor antagonists on dependence-induced increases in alcohol drinking by alcohol-preferring (P) rats. Alcohol Clin Exp Res 2008; 32(9): 1535-42.
102. Gehlert DR, Cippitelli A, Thorsell A, et al. 3-(4-Chloro-2- morpholin-4-yl-thiazol-5- yl)-8-(1-ethylpropyl)-2,6-dimethylimidazo[ 1,2-b]pyridazine: a novel brain penetrant, orally available corticotropin-releasing factor receptor 1 antagonist with efficacy in animal models of alcoholism. J Neurosci 2007; 27: 2718-26.
103. Sommer WH, Rimondini R, Hansson AC, et al. Upregulation of voluntary alcohol intake, behavioural sensitivity to stress, and amygdala crhr1 expression following a history of dependence. Biol Psychiatry 2008; 63(2): 139-45.
104. Vaughan J, Donaldson C, Bittencourt J, et al. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropinreleasing factor. Nature 1995; 378(6554): 287-92.
105. Hsu SY, Hsueh AJ. Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nat Med 2001; 7(5): 605-11.
106. Reyes TM, Lewis K, Perrin MH, et al. Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci USA 2001; 98(5): 2843-8.
107. Ryabinin AE, Tsivkovskaia NO, Ryabinin SA. Urocortin 1- containing neurons in the human Edinger-Westphal nucleus. Neuroscience 2005; 134(4): 1317-23.
108. Bittencourt JC, Vaughan J, Arias C, et al. Urocortin expression in rat brain: evidence against a pervasive relationship of urocortincontaining projections with targets bearing type 2 CRF receptors. J Comp Neurol 1999; 415(3): 285-312.
109. Bachtell RK, Weitemier AZ, Ryabinin AE. Lesions of the Edinger- Westphal nucleus in C57BL/6J mice disrupt ethanol-induced hypothermia and ethanol consumption. Eur J Neurosci 2004; 20: 1613- 23.
110. Chang SL, Patel NA, Romero AA. Activation and desensitization of Fos immunoreactivity in the rat brain following ethanol administration. Brain Res1995; 679: 89-98.
111. Ryabinin AE, Criado JR, Henriksen SJ, et al. Differential sensitivity of c-Fos expression in hippocampus and other brain regions to moderate and low doses of alcohol. Mol Psychiatry 1997; 2: 32-43.
112. Bachtell RK, Ryabinin AE. Interactive effects of nicotine and alcohol co-administration on expression of inducible transcription factors in mouse brain. Neuroscience 2001; 103: 941-54.
113. Knapp DJ, Braun CJ, Duncan GE, et al. Regional specificity of ethanol and NMDA action in brain revealed with FOS-like immunohistochemistry and differential routes of drugadministration. Alcohol Clin Exp Res 2001; 25: 1662-72.
114. Kolodziejska-Akiyama KM, Cha YM, Jiang Y, et al. Ethanolinduced FOS immunoreactivity in the brain of mu-opioid receptor knockout mice. Drug Alcohol Depend 2005; 80: 161-8.
115. Topple AN, Hunt GE, McGregor IS. Possible neural substrates of beer-craving in rats. Neurosci. Lett. 1998; 252: 99-102.
116. Bachtell RK, Wang YM, Freeman P, et al. Alcohol drinking produces brain region-selective changes in expression of inducible transcription factors. BrainRes 1999; 847: 157-65.
117. Ryabinin AE, Bachtell RK, Freeman P, et al. ITF expression in mouse brain during acquisition of alcohol self-administration. Brain Res 2001; 890: 192-5.
118. Weitemier AZ, Woerner A, Backstrom P, et al. Expression of c-Fos in Alko alcohol rats responding for ethanol in an operant paradigm. Alcohol Clin Exp Res 2001; 25: 704-10.
119. Ryabinin AE, Galvan-Rosas A, Bachtell RK, et al. High alcohol/ sucrose consumption during dark circadian phase in C57BL/6J mice: involvement of hippocampus, lateral septum and urocortinpositive cells of the Edinger-Westphal nucleus. Psychopharmacology (Berlin) 2003; 165: 296-305.
120. Bachtell RK, Weitemier AZ, Galvan-Rosas A, et al. The Edinger-Westphal-lateral septum urocortin pathway and its relationship to alcohol consumption. J. Neurosci 2003; 23: 2477-87.
121. Sharpe AL, Tsivkovskaia NO, Ryabinin AE. Ataxia and c-Fos expression in mice drinking ethanol in a limited access session. Alcohol Clin Exp Res 2005; 29: 1419-26.
122. Weitemier AZ, Ryabinin AE. Brain region-specific regulation of urocortin1 innervation and corticotropin-releasing factor receptor type 2 binding by ethanol exposure. Alcohol Clin Exp Res 2005; 29(9): 1610-20.
123. Bachtell RK, Tsivkovskaia NO, Ryabinin AE. Strain differences in urocortin expression in the Edinger-Westphal nucleus and its relation to alcohol-induced hypothermia. Neuroscience 2002; 113(2): 421-34.
124. Bachtell RK, Weitemier AZ, Galvan-Rosas A, et al. The Edinger-Westphal-lateral septum urocortin pathway and its relationship to alcohol consumption. J Neurosci 2003; 23: 2477-87.
125. Kiianmaa K, Hyytiä P, Samson HH, et al. New neuronal networks involved in ethanol reinforcement. Alcohol Clin Exp Res 2003; 27(2): 209-19.
126. Bachtell RK, Weitemier AZ, Galvan-Rosas A, et al. The Edinger- Westphal-lateral septum urocortin pathway and its relationship to alcohol consumption. J Neurosci 2003; 23: 2477-87.
127. Weitemier AZ, Ryabinin AE. Lesions of the Edinger-Westhal nucleus alter food consumption. Behav Neurosci 2005; 119: 1235- 43.
128. Turek VF, Tsivkovskaia NO, Hyytia P, et al. Urocortin 1 expression in five pairs of rat lines selectively bred for differences in alcohol drinking. Psychopharmacology (Berlin) 2005; 181: 511-7.
129. Bachtell RK, Weitemier AZ, Ryabinin AE. Lesions of the Edinger- Westphal nucleus in C57BL/6J mice disrupt ethanol-induced hypothermia and ethanol consumption. Eur J Neurosci 2004; 20: 1613- 23.
130. Gonzales RA, Job MO, Doyon WM. The role of mesolimbic dopamine in the development and maintenance of ethanol reinforcement. Pharmacol Ther 2004; 103: 121-46.
131. Liu J, Yu B, Neugebauer V, et al. Corticotropin-releasing factor and Urocortin I modulate excitatory glutamatergic synaptic transmission. J Neurosci 2004; 24: 4020-9.
132. Liu J, Yu B, Orozco-Cabal L, et al. Chronic cocaine administration switches corticotropin-releasing factor2 receptor-mediated depression to facilitation of glutamatergic transmission in the lateral septum. J Neurosci 2005; 25: 577-83.
133. Ryabinin AE, Weitemier AZ. The urocortin 1 neurocircuit: ethanolsensitivity and potential involvement in alcohol consumption. Brain Res Rev 2006; 52(2): 368-80.
134. Ryabinin AE, Yoneyama N, Tanchuck MA, et al. Urocortin 1 microinjection into the mouse lateral septum regulates the acquisition and expression of alcohol consumption. Neuroscience 2008; 151(3): 780-90.
135. Valdez GR, Sabino V, Koob GF. Increased anxiety-like behavior and ethanol self-administration in dependent rats: reversal via corticotropin- releasing factor-2 receptor activation. Alcohol Clin Exp Res 2004; 28(6): 865-72.
136. Smith GW, Aubry JM, Dellu F, et al. Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 1998; 20(6): 1093-102.
137. Bale TL, Contarino A, Smith GW, et al. Mice deficient for corticotropin- releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nat Genet 2000; 24(4): 410-4.
138. Bale TL, Picetti R, Contarino A, et al. Mice deficient for both corticotropin-releasing factor receptor 1 (CRFR1) and CRFR2 have an impaired stress response and display sexually dichotomous anxiety-like behaviour. J Neurosci 2002; 22(1): 193-9.
139. Heilig M, McLeod S, Brot M, et al. Anxiolytic-like action of neuropeptide Y: mediation by Y1 receptors in amygdala, and dissociation from food intake effects. Neuropsychopharmacology 1993; 8(4): 357-63.
140. Broqua P, Wettstein JG, Rocher MN, et al. Behavioral effects of neuropeptide Y receptor agonists in the elevated plus-maze and fear-potentiated startle procedures. Behav Pharmacol 1995; 6(3): 215-22.
141. Britton KT, Southerland S, Van Uden E, et al. Anxiolytic activity of NPY receptor agonists in the conflict test. Psychopharmacology (Berl) 1997; 132(1): 6-13.
142. Stogner KA, Holmes PV. Neuropeptide-Y exerts antidepressantlike effects in the forced swim test in rats. Eur J Pharmacol 2000; 387(2): R9-10.
143. Redrobe JP, Dumont Y, Fournier A, et al. The neuropeptide Y (NPY) Y1 receptor subtype mediates NPY-induced antidepressantlike activity in the mouse forced swimming test. Neuropsychopharmacology 2002; 26(5): 615-24.
144. Redrobe JP, Dumont Y, Quirion R. Neuropeptide Y (NPY) and depression: from animal studies to the human condition. Life Sci 2002; 71(25): 2921-37.
145. Wahlestedt C, Yanaihara N, Hakanson R. Evidence for different pre- and post-junctional receptors for neuropeptide Y and related peptides. Regul Pept 1986; 13: 307-18.
146. Thorsell A, Svensson P, Wiklund L, et al. Suppressed neuropeptide Y (NPY) mRNA in rat amygdala following restraint stress. Regul Pept 1998; 75-76: 247-54.
147. Thorsell A, Carlsson K, Ekman R, et al. Behavioral and endocrine adaptation, and up-regulation of NPY expression in rat amygdala following repeated restraint stress. Neuroreport 1999; 10(14): 3003-7.
148. Thiele TE, Marsh DJ, Ste Marie L, et al. Ethanol consumption and resistance are inversely related to neuropeptide Y levels. Nature 1998; 396(6709): 366-9.
149. Zhang H, Sakharkar AJ, Shi G, et al. Neuropeptide y signaling in the central nucleus of amygdala regulates alcohol-drinking and anxiety-like behaviors of alcohol-preferring rats. Alcohol Clin Exp Res 2010; 34(3): 451-61.
150. Ehlers CL, Somes C, Cloutier D. Are some of the effects of ethanol mediated through NPY? Psychopharmacology (Berl) 1998; 139(1-2): 136-44.
151. Hwang BH, Suzuki R, Lumeng L, et al. Innate differences in neuropeptide Y (NPY) mRNA expression in discrete brain regions between alcohol-preferring (P) and -nonpreferring (NP) rats: a significantly low level of NPY mRNA in dentate gyrus of the hippocampus and absence of NPY mRNA in the medial habenular nucleus of P rats. Neuropeptides 2004; 38(6): 359-68.
152. Hwang BH, Zhang JK, Ehlers CL, et al. Innate differences of neuropeptide Y (NPY) in hypothalamic nuclei and central nucleus of the amygdale between selectively bred rats with high and low alcohol preference. Alcohol Clin Exp Res 1999; 23(6): 1023-30.
153. Suzuki R, Lumeng L, McBride WJ, et al. Reduced neuropeptide Y mRNA expression in the central nucleus of amygdala of alcohol preferring (P) rats: its potential involvement in alcohol preference and anxiety. Brain Res 2004; 1014(1-2): 251-4.
154. Thorsell A, Repunte-Canonigo V, O'Dell LE, et al. Viral vectorinduced amygdala NPY overexpression reverses increased alcohol intake caused by repeated deprivations in Wistar rats. Brain 2007; 130(Pt 5): 1330-7.
155. Cippitelli A, Damadzic R, Hansson AC, et al. Neuropeptide Y (NPY) suppresses yohimbine-induced reinstatement of alcohol seeking. Psychopharmacology (Berl) 2010; 208(3): 417-26.
156. Thorsell A, Rimondini R, Heilig M. Blockade of central neuropeptide Y (NPY) Y2 receptors reduces ethanol self-administration in rats. Neurosci Lett 2002; 332(1): 1-4.
157. Rimondini R, Thorsell A, Heilig M. Suppression of ethanol selfadministration by the neuropeptide Y (NPY) Y2 receptor antagonist BIIE0246: evidence for sensitization in rats with a history of dependence. Neurosci Lett 2005; 375(2): 129-33.
158. Meunier JC, Mollereau C, Toll L, et al. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 1995; 377: 532-5.
159. Mogil JS, Grisel JE, Reinscheid RK, et al. Orphanin FQ is a functional anti-opioid peptide. Neuroscience 1996; 75: 333-7.
160. Mogil JS, Grisel JE, Zhangs G, et al. Functional antagonism of μ-, δ- and κ-opioid antinociception by orphanin FQ. Neurosci Lett 1996; 214: 131-4.
161. Ciccocioppo R, Angeletti S, Sanna PP, et al. Effect of nociceptin/orphanin FQ on the rewarding properties of morphine. Eur J Pharmacol 2000; 404: 153-9.
162. Di Giannuario A, Pieretti S. Nociceptin differentially affects morphine- induced dopamine release from the nucleus accumbens and nucleus caudate in rats. Peptides 2000; 21: 1125-30.
163. Martin-Fardon R, Zorrilla EP, Ciccocioppo R, et al. Role of innate anddrug-induced dysregulation of brain stress and arousal systems in addiction: Focus on corticotropin-releasing factor, nociceptin/orphanin FQ, and orexin/hypocretin. Brain Res 2010; 1314: 145-61.
164. Xuei X, Flury-Wetherill L, Almasy L, et al. Association analysis of genes encoding the nociceptin receptor (OPRL1) and its endogenous ligand (PNOC) with alcohol or illicit drug dependence. Addict Biol 2008; 13: 80-7.
165. Huang J, Young B, Pletcher MT, et al. Association between the nociceptin receptor gene (OPRL1) single nucleotide polymorphisms and alcohol dependence. Addict Biol 2008; 13(1): 88-94.
166. Ciccocioppo R, Economidou D, Fedeli A, et al. Attenuation of ethanol self-administration and of conditioned reinstatement of alcohol-seeking behaviour by the antiopioid peptide nociceptin/orphanin FQ in alcohol-preferring rats. Psychopharmacology (Berl) 2004; 172(2): 170-8.
167. Economidou D, Fedeli A, Fardon RM, et al. Effect of novel nociceptin/ orphanin FQ-NOP receptor ligands on ethanol drinking in alcohol-preferring msP rats. Peptides 2006; 27(12): 3299-306.
168. Kuzmin A, Kreek MJ, Bakalkin G, et al. The nociceptin/orphanin FQ receptor agonist Ro 64-6198 reduces alcohol selfadministration and prevents relapse-like alcohol drinking. Neuropsychopharmacology 2007; 32: 902-10.
169. Ciccocioppo R, Economidou D, Fedeli A, et al. The nociceptin/orphanin FQ/NOP receptor system as a target for treatment of alcohol abuse: a review of recent work in alcohol-preferring rats. Physiol Behav 2003; 79: 121-8.
170. Martin-Fardon R, Ciccocioppo R, Massi M, et al. Nociceptin prevents stress-induced ethanol- but not cocaine-seeking behaviour in rats. Neuroreport 2000; 11: 1939-43.
171. Ciccocioppo R, Economidou D, Fedeli A, et al. Attenuation of ethanol self-administration and of conditioned reinstatement of alcohol- seeking behaviour by the antiopioid peptide nociceptin/ orphanin FQ in alcohol-preferring rats. Psychopharmacology (Berl.) 2004; 172: 170-8.
172. Economidou D, Fedeli A, Fardon RM, et al. Effect of novel nociceptin/ orphanin FQNOP receptor ligands on ethanol drinking in alcohol- preferring msP rats. Peptides 2006; 27: 3299-306.
173. Economidou D, Hansson AC, Weiss F, et al. Dysregulation of nociceptin/orphanin FQ activity in the amygdala is linked to excessive alcohol drinking in the rat. Biol Psychiatry 2008; 64: 211-8.
174. Ciccocioppo R, Economidou D, Rimondini R, et al. Buprenorphine reduces alcohol drinking through activation of the nociceptin/ orphanin FQ-NOP receptor system. Biol Psychiatry 2007; 61: 4-12.
175. Kakko J, Svanborg KD, Kreek MJ, et al. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised,placebocontrolled trial. Lancet 2003; 361: 662-8.
176. Euler US, Gaddum JH. An unidentified depressor substance in certain tissue extracts. J Physiol 1931; 72(1): 74-87.
177. Fernandes ES, Schmidhuber SM, Brain SD. Sensory-nerve-derived neuropeptides: possible therapeutic targets. Handb Exp Pharmacol 2009; (194): 393-416.
178. Heilig M, Thorsell A, Sommer WH, et al. Translating the neuroscience of alcoholism into clinical treatments: From blocking the buzz to curing the blues. Neurosci Biobehav Rev 2009 [Epub ahead of print].
179. Kramer MS, Cutler N, Feighner J, et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998; 281(5383): 1640-5.
180. Kramer MS, Winokur A, Kelsey J, et al. Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology 2004; 29(2): 385-92.
181. Furmark T, Appel L, Michelgård A, et al. Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol Psychiatry 2005; 58(2): 132-42.
182. Holmes A, Heilig M, Rupniak NM, et al. Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol Sci 2003; 24(11): 580-8.
183. George DT, Gilman J, Hersh J, et al. Neurokinin 1 receptor antagonism as a possible therapy for alcoholism. Science 2008; 319(5869): 1536-9.
184. Seneviratne C, Ait-Daoud N, Ma JZ, et al. Susceptibility locus in neurokinin-1 receptor gene associated with alcohol dependence. Neuropsychopharmacology 2009; 34(11): 2442-9.
185. Ciccocioppo R, Panocka I, Polidori C, et al. Mechanism of action for reduction of ethanol intake in rats by the tachykinin NK-3 receptor agonist aminosenktide. Pharmacol Biochem Behav 1998; 61(4): 459-64.
186. Massi M, Panocka I, deCaro G. The psychopharmacology of tachykinin NK-3 receptors in laboratory animals. Peptides 2000; 21: 1597-609.
187. Ciccocioppo R, Panocka I, Pompei P, et al. Selective agonists at NK3 tachykinin receptors inhibit alcohol intake in Sardinian alcohol- preferring rats. Brain Res Bull 1994; 33: 71-7.
188. Ciccocioppo R, Panocka I, Pompei P, et al. Subcutaneous injections of the tachykinin senktide reduce alcohol intake in alcoholpreferring rats. Peptides 1995; 16: 533-7.
189. Panocka I, Ciccocioppo R, Polidori C, et al. Sensitivity of brain sites to the inhibitory effect on alcohol intake of the tachykinin aminosenktide. Peptides 1998; 19(5): 897-905.
190. Foroud T, Wetherill LF, Kramer J, et al. The tachykinin receptor 3 is associated with alcohol and cocaine dependence. Alcohol Clin Exp Res 2008; 32(6): 1023-30.
191. Ahlstedt I, Engberg S, Smith J, et al. Occurrence and pharmacological characterization of four human tachykinin NK2 receptor variants. Biochem Pharmacol 2008; 76(4): 476-81.
192. Louis C, Stemmelin J, Boulay D, et al. Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models. Pharmacol Biochem Behav 2008; 89(1): 36-45.
193. Ciccocioppo R, Panocka I, Pompei P, et al. Selective agonists at NK3 tachykinin receptors inhibit alcohol intake in Sardinian alcohol- preferring rats. Brain Res Bull 1994; 33(1): 71-7.
194. Reinscheid RK. Phylogenetic appearance of neuropeptide S precursor proteins in tetrapods. Peptides 2007; 28(4): 830-7.
195. Reinscheid RK, Xu YL. Neuropeptide S as a novel arousal promoting peptide transmitter. FEBS J 2005; 272(22): 5689-93.
196. Pape HC, Jüngling K, Seidenbecher T, et al. Neuropeptide S: a transmitter system in the brain regulating fear and anxiety. Neuropharmacology 2010; 58(1): 29-34.
197. Ruggeri B, Braconi S, Cannella N, et al. Neuropeptide s receptor gene expression in alcohol withdrawal and protracted abstinence in postdependent rats. Alcohol Clin Exp Res 2010; 34(1): 90-7.
198. Liu X, Weiss F. Additive effect of stress and drug cues on reinstatement of ethanol seeking: exacerbation by history of dependence and role of concurrent activation of corticotropin-releasing factor and opioid mechanisms. J Neurosci 2002; 22: 7856-61.
199. Cannella N, Economidou D, Kallupi M, et al. Persistent increase of alcohol-seeking evoked by neuropeptide S: an effect mediated by the hypothalamic hypocretin system. Neuropsychopharmacology 2009; 34: 2125-34.
200. Badia-Elder NE, Henderson AN, Bertholomey ML, et al. The effects of neuropeptide S on ethanol drinking and other related behaviours in alcohol-preferring and -nonpreferring rats. Alcohol Clin Exp Res 2008; 32: 1380-7.
201. Jungling K, Seidenbecher T, Sosulina L, et al. Neuropeptide Smediated control of fear expression and extinction: role of intercalated GABAergic neurons in the amygdala. Neuron 59: 298-310.
202. Xu YL, Reinscheid RK, Huitron-Resendiz S, et al. Neuropeptide S: a neuropeptide promoting arousal and anxiolytic-like effects. Neuron 2008; 43: 487-97.
203. Mitsukawa K, Lu X, Bartfai T. Galanin, galanin receptors and drug targets. Cell Mol Life Sci 2008; 65: 1796-805.
204. Belfer I, Hipp H, Bollettino A, et al. Alcoholism is associated with GALR3 but not two other galanin receptor genes. Genes Brain Behav 2007; 6(5): 473-81.
205. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormonereleasing acylated peptide from stomach. Nature 1999, 402(6762): 656-60.
206. Loose MD, Ronnekleiv OK, Kelly MJ. Neurons in the rat arcuate nucleus are hyperpolarized by GABAB and mu-opioid receptor agonists: evidence for convergence at a ligandgated potassium conductance. Neuroendocrinology 1991; 54(6): 537-44.
207. Katayama M, Nogami H, Nishiyama J, et al. Developmentally and regionally regulated expression of growth hormone secretagogue receptor mRNA in rat brain and pituitary gland. Neuroendocrinology 2000; 72(6): 333-40.
208. Zigman JM, Jones JE, Lee CE, et al. Expression of ghrelin receptor mRNA in the rat and the mouse brain. J Comp Neurol 2006; 494(3): 528-48.
209. Jerlhag E, Egecioglu E, Dickson SL, et al. Ghrelin stimulates locomotor activity and accumbal dopamine-overflow via central cholinergic systems in mice: Implications for its involvement in brain reward. Addict Biol 2006; 11(1): 45-54.
210. Jerlhag E, Egecioglu E, Dickson SL, et al. Ghrelin administration into tegmental areas stimulates locomotor activity and increases extracellular concentration of dopamine in the nucleus accumbens. Addict Biol 2007; 12(1): 6-16.
211. Jerlhag E, Egecioglu E, Dickson SL, et al. Alpha-conotoxin MIIsensitive nicotinic acetylcholine receptors are involved in mediating the ghrelin-induced locomotor stimulation and dopamine overflow in nucleus accumbens. Eur Neuropsychopharmacol 2008; 18(7): 508-18.
212. Jerlhag E. Systemic administration of ghrelin induces conditioned place preference and stimulates accumbal dopamine. Addict Biol 2008; 13(3-4): 358-63.
213. Jerlhag E, Egecioglu E, Landgren S. et al. Requirement of central ghrelin signaling for alcohol reward. Proc Natl Acad Sci USA 2009; 106(27): 11318-23.
214. Leggio L. Role of the ghrelin system in alcoholism: Acting on the growth hormone secretagogue receptor to treat alcohol-related diseases. Drug News Perspect 2010; 23(3): 157-66.
215. Barroso-Chinea P, Cruz-Muros I, Aymerich MS, et al. Striatal expression of GDNF and differential vulnerability of midbrain dopaminergic cells. Eur J Neurosci 2005; 21: 1815-27.
216. Carnicella S, Ron D. GDNF--a potential target to treat addiction. Pharmacol Ther 2009; 122(1): 9-18.
217. Koob GF, Sanna PP, Bloom FE. Neuroscience of addiction. Neuron 1998; 21, 467-476.
218. He DY, McGough NN, Ravindranathan A, et al. Glial cell linederived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption. J Neurosci 2005; 25: 619-28.
219. Carnicella S, Kharazia V, Jeanblanc J, et al. GDNF is a fastacting potent inhibitor of alcohol consumption and relapse. Proc Natl Acad Sci USA 2008; 105: 8114-9.
220. Carnicella S, Ron D. GDNF--a potential target to treat addiction. Pharmacol Ther 2009; 122(1): 9-18.
221. Yang F, Feng L, Zheng F, et al. GDNF acutely modulates excitability and A-type K(+) channels in midbrain dopaminergic neurons. Nat Neurosci 2001; 4: 1071-8.
222. Consales C, Volpicelli F, Greco D, et al. GDNF signaling in embryonic midbrain neurons in vitro. Brain Res 2007; 1159: 28-39.
223. He DY, Ron D. Autoregulation of glial cell line-derived neurotrophic factor expression: implications for the long-lasting actions of the anti-addiction drug, Ibogaine. FASEB J 2006; 20: 2420-2.
224. Belin D, Deroche-Gamonet V, Jaber M. Cocaine-induced sensitization is associated with altered dynamics of transcriptional responses of the dopamine transporter, tyrosine hydroxylase, and dopamine D2 receptors in C57Bl/6J mice. Psychopharmacology (Berl) 2007; 193: 567-78.
225. Kastin AJ, Akerstrom V, Pan W. Glial cell line-derived neurotrophic factor does not enter normal mouse brain. Neurosci Lett 2003; 340: 239-41.
226. Maciulaitis R, Kontrimaviciute V, Bressolle FM, et al. Ibogaine, an anti-addictive drug: pharmacology and time to go further in development. A narrative review. Hum Exp Toxicol 2008; 27: 181-94.
227. He DY, McGough NN, Ravindranathan A, et al. Glial cell linederived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption. J Neurosci 2005; 25: 619-28.
228. Maisonneuve IM, Glick SD. Anti-addictive actions of an iboga alkaloid congener: a novel mechanism for a novel treatment. Pharmacol Biochem Behav 2003; 75, 607-18.
229. Ohta K, Fujinami A, Kuno S, et al. Cabergoline stimulates synthesis and secretion of nerve growth factor, brainderived neurotrophic factor and glial cell line-derived neurotrophic factor by mouse astrocytes in primary culture. Pharmacology 2004; 71: 162-8.
230. Carnicella S, Ahmadiantehrani S, He DY, et al. The FDA-approved drug cabergoline decreases alcohol drinking and seeking behaviours via glial cell line-derived neurotrophic factor. Biol Psychiatry 2009 in revision.
231. Raskin NH. Alcoholism or acetaldehydism? N Engl J Med 1975; 292: 422-3.
232. Amit Z, Smith BR. A multi-dimensional examination of the positive reinforcing properties of acetaldehyde. Alcohol 1985; 2: 367- 70.
233. Brown ZW, Amit Z, Rockman GE. Intraventricular selfadministration of acetaldehyde, but not ethanol, in naive laboratory rats. Psychopharmacology 1979; 64: 271-6.
234. Rodd-Henricks ZA, Melendez RI, Zaffaroni A, et al. The reinforcing effects of acetaldehyde in the posterior ventral tegmental area of alcohol-preferring rats. Pharmacol. Biochem Behav 2002; 72: 55-64.
235. Smith BR, Amit Z, Splawinsky J. Conditioned place preference induced by intraventricular infusions of acetaldehyde. Alcohol 1984; 1: 193-5.
236. Quertemont E, De Witte P. Conditioned stimulus preference after acetaldehyde but not ethanol injections. Pharmacol Biochem Behav 2001; 68: 449-54.
237. Quintanilla ME, Tampier L. Acetaldehyde-reinforcing effects: differences in low-alcohol-drinking (UChA) and high-alcoholdrinking(UChB) rats. Alcohol 2003; 31: 63-9.
238. Myers WD, Ng KT, Marzuki S, et al. Alteration of alcohol drinking in the rat by peripherally self-administered acetaldehyde. Alcohol 1984; 1: 229-36.
239. Myers WD, Ng KT, Singer G. Ethanol preference in rats with a prior history of acetaldehyde self-administration. Experientia 1984; 40: 1008-10.
240. Melis M, Enrico P, Peana AT, et al. Acetaldehyde mediates alcohol activation of the mesolimbic dopamine system. Eur J Neurosci 2007; 6, 2824-33.
241. Diana M, Peana AT, Sirca D, et al. Crucial role of acetaldehyde in alcohol activation of the mesolimbic dopamine system. Ann NY Acad Sci 2008; 1139: 307-17.
242. Melis M, Diana M, Enrico P, et al. Ethanol and acetaldehyde action on central dopamine systems: mechanisms, modulation, and relationship to stress. Alcohol 2009; 43(7): 531-9.
243. Salaspuro V, Hietala J, Kaihovaara P, et al. Removal of acetaldehyde from saliva by a slow-release buccal tablet of L-cysteine. Int J Cancer 2002; 97(3): 361-4.
244. Salaspuro VJ, Hietala JM, Marvola ML, et al. Eliminating carcinogenic acetaldehyde by cysteine from saliva during smoking. Cancer Epidemiol Biomarkers Prev 2006; 15(1): 146-9.
245. Salaspuro M. Interrelationship between alcohol, smoking, acetaldehyde and cancer. Novartis Found Symp 2007; 285: 80-9; discussion 89-96, 198-9.
246. Shackebaei D, King N, Shukla B, et al. Mechanisms underlying the cardioprotective effect of L-cysteine. Mol Cell Biochem 2005; 277(1-2): 27-31. PubMed PMID: 16132711.
247. Sprince H, Parker CM, Smith GG, et al. Protection against acetaldehyde toxicity in the rat by L-cysteine, thiamin and L-2- methylthiazolidine-4-carboxylic acid. Agents Actions 1974; 4(2): 125-30.
248. Peana AT, Assaretti AR, Muggironi G, et al. Reduction of ethanolderived acetaldehyde induced motivational properties by Lcysteine. Alcohol Clin Exp Res 2009; 33(1): 43-8.
249. Peana AT, Muggironi G, Calvisi G, et al. l-Cysteine reduces oral ethanol self-administration and reinstatement of ethanol-drinking behaviour in rats. Pharmacol Biochem Behav 2010; 94(3): 431-7.
250. Eriksson CJ. The role of acetaldehyde in the actions of alcohol (update 2000). Alcohol Clin Exp Res 2001; 25, S5: 15S-32.
251. Quintanilla ME, Tampier L, Sapag A, et al. Polymorphisms in the mitochondrial aldehyde dehydrogenase gene (Aldh2) determine peak blood acetaldehyde levels and voluntary ethanol consumption in rats. Pharmacogenet Genomics 2005; 15: 427-31.
252. Suh JJ, Pettinati HM, Kampman KM, et al. The status of disulfiram: a half of a century later [see comment]. J Clin Psychopharmacol 2006; 26: 290-302.
253. Keung WM, Vallee BL. Kudzu root: an ancient Chinese source of modern antidipsotropic agents. Phytochemistry 1998; 47(4): 499- 506.
254. Keung WM, Vallee BL. Daidzin: a potent, selective inhibitor of human mitochondrial aldehyde dehydrogenase. Proc Natl Acad Sci USA 1993; 90: 1247-351.
255. Lin RC, Guthrie S, Xie CI, et al. Isoflavonoid compounds extracted from Pueraria lobata suppress alcohol preference in a pharmacogenetic rat model for alcoholism. Alcohol Clin Exp Res 1996; 20: 659-63.
256. Heyman GM, Keung WM, Vallee BL. Daidzin decreases ethanol consumption in rats. Alcohol Clin Exp Res 1996; 20: 1083-7.
257. Overstreet DH, Lee YW, Rezvani AH, et al. Suppression of alcohol intake after administration of the Chinese herbal medicine, NPI-028, and its derivatives. Alcohol Clin Exp Res 1996; 20: 221-7.
258. Overstreet DH, Lee DYW, Chen YT, et al. The Chinese herbal medicine NPI-028 suppresses alcohol intake in alcoholpreferring rats and monkeys without inducing taste aversion. Perfusion 1998; 11: 381-90.
259. Benlhabib E, Baker JI, Keyler DE, et al. Kudzu root extract suppresses voluntary alcohol intake and alcohol withdrawal symptoms in P rats receiving free access to water and alcohol. J Med Food. 2004; 7(2): 168-79.
260. Benlhabib E, Baker JI, Keyler DE, et al. Effects of purified puerarin on voluntary alcohol intake and alcohol withdrawal symptoms in P rats receiving free access to water and alcohol. J Med Food 2004; 7(2): 180-6.
261. Arolfo MP, Overstreet DH, Yao L, et al. Suppression of heavy drinking and alcohol seeking by a selective ALDH-2 inhibitor. Alcohol Clin Exp Res 2009; 33(11): 1935-44.
262. Xie CI, Lin RC, Antony V, et al. Daidzin, an antioxidant isoflavonoid, decreases blood alcohol levels and shortens sleep time induced by ethanol intoxication. Alcohol Clin Exp Res 1994; 18(6): 1443-7.
263. Carai MA, Agabio R, Bombardelli E,et al. Potential use of medicinal plants in the treatment of alcoholism. Fitoterapia 2000; 71, S1: S38-42.
264. Overstreet DH, Kralic JE, Morrow AL, et al. NPI-031G (puerarin) reduces anxiogenic effects of alcohol withdrawal or benzodiazepine inverse or 5-HT2C agonists. Pharmacol Biochem Behav 2003; 75(3): 619-25.
265. Shebek J, Rindone JP. A pilot study exploring the effect of kudzu root on the drinking habits of patients with chronic alcoholism. J Altern Complement Med 2000; 6(1): 45-8.
266. Lukas SE, Penetar D, Berko J, et al. An extract of the Chinese herbal root kudzu reduces alcohol drinking by heavy drinkers in a naturalistic setting. Alcohol Clin Exp Res 2005; 29(5): 756-62.
267. Crunelle CL, Miller ML, Booij J, et al. The nicotinic acetylcholine receptor partial agonist varenicline and the treatment of drug dependence: a review. Eur Neuropsychopharmacol 2010; 20(2): 69- 79.
268. Clarke PB, Fu DS, Jakubovic A, et al. Evidence that mesolimbic dopaminergic activation underlies the locomotor stimulant action of nicotine in rats. J Pharmacol Exp Ther 1998; 246: 701-8.
269. Vengeliene V, Bilbao A, Molander A, et al. Neuropharmacology of alcohol addiction. Br J Pharmacol 2008; 154(2): 299-315.
270. Blomqvist O, Ericson M, Johnson DH, et al. Voluntary ethanol intake in the rat: effects of nicotinic acetylcholine receptor blockade or subchronic nicotine treatment. Eur J Pharmacol 1996; 314(3): 257-67.
271. Blomqvist O, Ericson M, Engel JA, et al. Accumbal dopamine overflow after ethanol: localization of the antagonizing effect of mecamylamine. Eur J Pharmacol 1997; 334 (2-3): 149-56.
272. Blomqvist O, Engel JA, Nissbrandt H, et al. The mesolimbic dopamine- activating properties of ethanol are antagonized by mecamylamine. Eur J Pharmacol 1993; 249(2): 207-13.
273. Ericson M, Blomqvist O, Engel JA, et al. Voluntary ethanol intake in the rat and the associated accumbal dopamine overflow are blocked by ventral tegmental mecamylamine. Eur J Pharmacol 1998; 358(3): 189-96.
274. Farook JM, Lewis B, Gaddis JG, et al. Effects of mecamylamine on alcohol consumption and preference in male C57BL/6J mice. Pharmacology 2009; 83(6): 379-84.
275. Kuzmin A, Jerlhag E, Liljequist S, et al. Effects of subunit selective nACh receptors on operant ethanol self-administration and relapse- like ethanol-drinking behaviour. Psychopharmacology (Berl) 2009; 203(1): 99-108.
276. Bell RL, Eiler BJ, Cook JB, et al. Nicotinic receptor ligands reduce ethanol intake by high alcohol-drinking HAD-2 rats. Alcohol 2009; 43(8): 581-92.
277. Jiménez-Ruiz C, Berlin I, Hering T. Varenicline: a novel pharmacotherapy for smoking cessation.Drugs 2009; 69(10): 1319-38.
278. Kamens HM, Andersen J, Picciotto MR. Modulation of ethanol consumption by genetic and pharmacological manipulation of nicotinic acetylcholine receptors in mice. Psychopharmacology (Berl) 2010. [Epub ahead of print]
279. Steensland P, Simms JA, Holgate J, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Proc Natl Acad Sci USA 2007; 104(30): 12518-23.
280. Gulick D, Gould TJ. Varenicline ameliorates ethanol-induced deficits in learning in C57BL/6 mice. Neurobiol Learn Mem 2008; 90(1): 230-6.
281. Blomqvist O, Hernandez-Avila CA, Van Kirk J, et al. Mecamylamine modifies the pharmacokinetics and reinforcing effects of alcohol. Alcohol Clin Exp Res 2002; 26(3): 326-31.
282. Chi H, de Wit H. Mecamylamine attenuates the subjective stimulant- like effects of alcohol in social drinkers. Alcohol Clin Exp Res 2003; 27(5): 780-6.
283. Young EM, Mahler S, Chi H, et al. Mecamylamine and ethanol preference in healthy volunteers. Alcohol Clin Exp Res. 2005; 29(1): 58-65.
284. McKee SA, Harrison EL, O'Malley SS, et al. Varenicline reduces alcohol self-administration in heavy drinking smokers. Biol Psychiatry 2009; 66(2): 185-90.
285. Zhou C, Fryer AD, Jacoby DB. Structure of the human M(2) muscarinic acetylcholine receptor gene and its promoter. Gene 2001; 271: 87-92.
286. Dick DM, Agrawal A, Wang JC, et al. Alcohol dependence with comorbid drug dependence: genetic and phenotypic associations suggest a more severe form of the disorder with stronger genetic contribution to risk. Addiction 2007; 102(7): 1131-9.
287. Luo X, Kranzler HR, Zuo L, et al. CHRM2 gene predisposes to alcohol dependence, drug dependence and affective disorders: results from an extended case-control structured association study. Hum Mol Genet 2005; 14(16): 2421-34.
288. Söderpalm B, Ericson M, Olausson P, et al. Nicotinic mechanisms involved in the dopamine activating and reinforcing properties of ethanol. Behav Brain Res 2000; 113(1-2): 85-96.
289. Samochocki M, Höffle A, Fehrenbacher A, et al. Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther 2003; 305(3): 1024-36.
290. Opitz K. Verwendung von galanthamin zur behandlung des alkoholismus, Patent DE 4010079, 1992.
291. Iliev A, Traykov V, Prodanov D, et al. N. Effect of the acetylcholinesterase inhibitor galanthamine on learning and memory in prolonged alcohol intake rat model of acetylcholine deficit. Methods Find Exp Clin Pharmacol 1999; 21(4): 297-301.
292. Doetkotte R, Opitz K, Kiianmaa K, et al. Reduction of voluntary ethanol consumption in alcohol-preferring Alko alcohol (AA) rats by desoxypeganine and galanthamine. Eur J Pharmacol 2005; 522(1-3): 72-7.
293. Mann K, Ackermann K, Diehl A, et al. Galantamine: a cholinergic patch in the treatment of alcoholism: a randomized, placebocontrolled trial. Psychopharmacology (Berl) 2006; 184(1): 115-21.
294. Gann H, Feige B, Hohagen F, et al. Sleep and the cholinergic rapid eye movement sleep induction test in patients with primary alcohol dependence. Biol Psychiatry 2001; 50(5): 383-90.
295. Di Chiara G, Imperato A. Ethanol preferentially stimulates dopamine release in the nucleus accumbens of freely moving rats. Eur J Pharmacol 1985; 115(1): 131-2.
296. Koob GF, Bloom FE. Cellular and molecular mechanisms of drug dependence. Science 1988; 242(4879): 715-23.
297. Schofield P. Glycine: the other inhibitory neurotransmitter. Alcohol Clin Exp Res 1996; 20(S8): 219A-23.
298. Zheng F, Johnson SW. Glycine receptor-mediated inhibition of dopamine and non-dopamine neurons of the rat ventral tegmental area in vitro. Brain Res 2001; 919(2): 313-7.
299. Aguayo LG, Tapia JC, Pancetti FC. Potentiation of the glycineactivated Cl- current by ethanol in cultured mouse spinal neurons. J Pharmacol Exp Ther 1996; 279(3): 1116-22.
300. Mascia MP, Machu TK, Harris RA. Enhancement of homomeric glycine receptor function by long-chain alcohols and anaesthetics. Br J Pharmacol 1996; 119(7): 1331-6.
301. Molander A, Söderpalm B. Glycine receptors regulate dopamine release in the rat nucleus accumbens. Alcohol Clin Exp Res 2005; 29(1): 17-26.
302. Molander A, Söderpalm B. Accumbal strychnine-sensitive glycine receptors: an access point for ethanol to the brain reward system. Alcohol Clin Exp Res 2005; 29(1): 27-37
303. Molander A, Löf E, Stomberg R, et al. Involvement of accumbal glycine receptors in the regulation of voluntary ethanol intake in the rat. Alcohol Clin Exp Res 2005; 29(1): 38-45.
304. Molander A, Lidö HH, Löf E, et al. The glycine reuptake inhibitor Org 25935 decreases ethanol intake and preference in male wistar rats. Alcohol Alcohol 2007; 42(1): 11-8.
305. Ge J, Hamilton M, Shahid D, et al. The effects of Org 25935 on the extracellular levels of glycine in brain regions of freely moving rats using microdialysis. Br J Pharmacology 2001; 133: 135.
306. Lidö HH, Stomberg R, Fagerberg A, et al. The glycine reuptake inhibitor org 25935 interacts with Basal and ethanol-induced dopamine release in rat nucleus accumbens. Alcohol Clin Exp Res 2009; 33(7): 1151-7.
307. Tully K, Li Y, Tsvetkov E, et al. Norepinephrine enables the induction of associative long-term potentiation at thalamo-amygdala synapses. PNAS 2007; 104(35): 14146-50.
308. Davis WM, Smith SG, Werner TE. Noradrenergic role in the selfadministration of ethanol. Pharmacol Biochem Behav 1978; 9: 369- 74.
309. Walker BM, Rasmussen DD, Raskind MA, et al. alpha1- noradrenergic receptor antagonism blocks dependence-induced increases in responding for ethanol. Alcohol 2008; 42(2): 91-7.
310. Mason BJ, Kocsis JH. Desipramine treatment of alcoholism. Psychopharmacol Bull 1991; 27: 155-61.
311. Mason BJ, Kocsis JH, Ritvo EC, et al. A double-blind, placebocontrolled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression. JAMA 1996; 275: 761-7.
312. Reid LD, Delconte JD, Amendola CA, et al. alpha(2)-Adrenoceptor antagonists and propensity to take alcoholic beverages. Behav Pharmacol 1994; 5(4 - 5): 485-93.
313. Marinelli PW, Funk D, Juzytsch W, et al. The CRF1 receptor antagonist antalarmin attenuates yohimbine-induced increases in operant alcohol self-administration and reinstatement of alcohol seeking in rats. Psychopharmacology (Berl) 2007; 195(3): 345-55.
314. Rasmussen DD, Alexander LL, Raskind MA, et al. The alpha1- adrenergic receptor antagonist, prazosin, reduces alcohol drinking in alcohol-preferring (P) rats. Alcohol Clin Exp Res 2009; 33(2): 264-72.
315. Simpson TL, Saxon AJ, Meredith CW, et al. A pilot trial of the alpha-1 adrenergic antagonist, prazosin, for alcohol dependence. Alcohol Clin Exp Res 2009; 33(2): 255-63.
316. Brodie MS, Scholz A, Weiger TM, et al. Ethanol interactions with calcium-dependent potassium channels. Alcohol Clin Exp Res 2007; 31(10): 1625-32.
317. Treistman SN, Martin GE. BK Channels: mediators and models for alcohol tolerance. Trends Neurosci 2009; 32(12): 629-37.
318. Brodie MS, McElvain MA, Bunney EB, et al. Pharmacological reduction of small conductance calcium-activated potassium current (SK) potentiates the excitatory effect of ethanol on ventral tegmental area dopamine neurons. J Pharmacol Exp Ther 1999; 290: 325-33.
319. Brodie MS, Pesold C, Appel SB. Ethanol directly excites dopaminergic ventral tegmental area reward neurons. Alcohol Clin Exper Res 1999; 23: 1848-52.
320. Hopf FW, Martin M, Chen BT, et al. Withdrawal from intermittent ethanol exposure increases probability of burst firing in VTA neurons in vitro. J Neurophysiol 2007; 98: 2297-310.
321. Brodie MS. Concurrent blockade of SK and h-current increases ethanol-induced excitation of dopaminergic ventral tegmental area neurons. Soc Neurosci Online 2005; Program No. 560.3.
322. Hopf FW, Bowers MS, Chang SJ, et al. Reduced nucleus accumbens SK channel activity enhances alcohol seeking during abstinence. Neuron 2010; 65: 682-94.
323. Ghezzi A, Al-Hasan YM, Larios LE, et al. slo K(+) channel gene regulation mediates rapid drug tolerance. Proc Natl Acad Sci USA 2004; 101(49): 17276-81.
324. Martin G, Puig S, Pietrzykowski A, et al. Somatic localization of a specific large-conductance calcium-activated potassium channel subtype controls compartmentalized ethanol sensitivity in the nucleus accumbens. J Neurosci 2004; 24(29): 6563-72.
325. Martin GE, Hendrickson LM, Penta KL, et al. Identification of a BK channel auxiliary protein controlling molecular and behavioral tolerance to alcohol. Proc Natl Acad Sci USA 2008; 105(45): 17543-8.
326. Dolganiuc A, Bakis G, Kodys K, et al. Acute ethanol treatment modulates Toll-like receptor-4 association with lipid rafts. Alcohol Clin Exp Res 2006; 30(1): 76-85.
327. Ellingson JS, Taraschi TF, Wu A, et al. Cardiolipin from ethanolfed rats confers tolerance to ethanol in liver mitochondrial membranes. Proc Natl Acad Sci USA 1988; 85(10): 3353-7.
328. Dunlap K, Luebke JI, Turner TJ. Exocytotic Ca2channels in mammalian central neurons. Trends Neurosci 1995; 18: 89-98.
329. Snutch TP. Targeting chronic and neuropathic pain: the N-type calcium channel comes of age. NeuroRx 2005; 2: 662-70.
330. Huguenard JR. Low-threshold calcium currents in central nervous system neurons. Annu Rev Physiol 1996; 58: 329-48.
331. Mu J, Carden WB, Kurukulasuriya NC, et al. Ethanol influences on native T-type calcium current in thalamic sleep circuitry. J Pharmacol Exp Ther 2003; 307: 197-204.
332. Reid CA, Bekkers JM, Clements JD. Presynaptic Ca2+ channels: a functional patchwork. Trends Neurosci 2003; 26(12): 683-7.
333. Newton PM, Orr CJ, Wallace MJ, et al. Deletion of N-type calcium channels alters ethanol reward and reduces ethanol consumption in mice. J Neurosci 2004; 24(44): 9862-9.
334. Newton PM, Zeng L, Wang V, et al. A blocker of N- and T-type voltage-gated calcium channels attenuates ethanol-induced intoxication, place preference, self-administration, and reinstatement. J Neurosci 2008; 28(45): 11712-9.
335. Martin WR, Eades CG, Thompson JA, et al. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine- dependent chronic spinal dog. J Pharmacol Exp Ther 1976; 197: 517-32.
336. Miyatake R, Furukawa A, Matsushita S, et al. Functional polymorphisms in the sigma1 receptor gene associated with alcoholism. Biol Psychiatry 2004; 55(1): 85-90.
337. Sabino V, Cottone P, Zhao Y, et al. The sigma-receptor antagonist BD-1063 decreases ethanol intake and reinforcement in animal models of excessive drinking. Neuropsychopharmacology 2009; 34(6): 1482-93.
338. Hadley ME, Haskell-Luevano C. The proopiomelanocortin system. Ann N Y Acad Sci 1999; 885: 1-21.
339. Kokare DM, Singru PS, Dandekar MP, et al. Involvement of alphamelanocyte stimulating hormone (alpha-MSH) in differential ethanol exposure and withdrawal related depression in rat: neuroanatomical- behavioural correlates. Brain Res 2008; 1216: 53-67.
340. Ploj K, Roman E, Kask A, et al. I. Effects of melanocortin receptor ligands on ethanol intake and opioid peptide levels in alcoholpreferring AA rats. Brain Res Bull 2002; 59(2): 97-104.
341. Navarro M, Cubero I, Knapp DJ, et al. MTII-induced reduction of voluntary ethanol drinking is blocked by pre-treatment with AgRP- (83-132). Neuropeptides 2003; 37(6): 338-44.
342. Navarro M, Cubero I, Chen AS, et al. Effects of melanocortin receptor activation and blockade on ethanol intake: a possible role for the melanocortin-4 receptor. Alcohol Clin Exp Res 2005; 29: 949-57.
343. Ebner K, Wotjak CT, Landgraf R, et al. Forced swimming triggers vasopressin release within the amygdala to modulate stress-coping strategies in rats. Eur J Neurosci 2002; 15(2): 384-8.
344. Wigger A, Sánchez MM, Mathys KC, et al. Alterations in central neuropeptide expression, release, and receptor binding in rats bred for high anxiety: critical role of vasopressin. Neuropsychopharmacology 2004; 29(1): 1-14.
345. Veinante P, Freund-Mercier MJ. Distribution of oxytocin- and vasopressin-binding sites in the rat extended amygdala: a histoautoradiographic study. J Comp Neurol 1997; 383(3): 305-25.
346. Gulya K, Dave JR, Hoffman PL. Chronic ethanol ingestion decreases vasopressin mRNA in hypothalamic and extrahypothalamic nuclei of mouse brain. Brain Res 1991; 557: 129-35.
347. Koob GF. A role for brain stress systems in addiction. Neuron 2008; 59(1): 11-34.
348. Umathe SN, Bhutada PS, Dixit PV, et al. Leuprolide: a luteinizing hormone releasing hormone agonist attenuates ethanol withdrawal syndrome and ethanol-induced locomotor sensitization in mice. Neuropeptides 2008; 42(3): 345-53.
349. Uday G, Pravinkumar B, Manish W, et al. LHRH antagonist attenuates the effect of fluoxetine on marble-burying behavior in mice. Eur J Pharmacol 2007; 563(1-3): 155-9.
350. Belelli D, Lambert JJ. Neurosteroids: endogenous regulators of the GABA(A)receptor. Nat Rev Neurosci 2005; 6(7): 565-75.
351. Patchev VK, Hassan AH, Holsboer DF, et al. The neurosteroid tetrahydroprogesterone attenuates the endocrine response to stress and exerts glucocorticoid-like effects on vasopressin gene transcription in the rat hypothalamus. Neuropsychopharmacology 1996; 15: 533-40.
352. Finn DA, Sinnott RS, Ford MM, Long SL, et al. Sex differences in the effect of ethanol injection and consumption on brain allopregnanolone levels in C57BL / 6 mice. Neuroscience 2004; 123: 813-9
353. Torres JM, Ortega E. Alcohol intoxication increases allopregnanolone levels in male adolescent humans. Psychopharmacology 2004; 172: 352-5.
354. Ford MM, Nickel JD, Phillips TJ, et al. Neurosteroid modulators of GABAA receptors differentially modulate ethanol intake patterns in male C57BL / 6J mice. Alcohol Clin Exp Res 2005; 29: 1630-40.
355. Ford MM, Nickel JD, Finn DA. Treatment with and withdrawal from finasteride alter ethanol intake patterns in male C57BL / 6J mice: potential role of endogenous neurosteroids? Alcohol 2005; 37: 23-33.
356. Pierucci-Lagha A, Covault J, Feinn R, et al. GABRA2 alleles moderate the subjective effects of alcohol, which are attenuated by finasteride. Neuropsychopharmacology 2005; 30: 1193-203.
357. Ford MM, Yoneyama N, Strong MN, et al. Inhibition of 5alphareduced steroid biosynthesis impedes acquisition of ethanol drinking in male C57BL/6J mice. Alcohol Clin Exp Res 2008; 32(8): 1408-16.
358. Melis M, Spiga S, Diana M. The dopamine hypothesis of drug addiction: hypodopaminergic state. Int Rev Neurobiol 2005; 63: 101-54.
359. Feil J, Zangen A. Brain stimulation in the study and treatment of addiction. Neurosci Biobehav Rev 2010; 34(4): 559-74.
360. Roth Y, Amir A, Levkovitz Y, et al. Three-dimensional distribution of the electric field induced in the brain by transcranial magnetic stimulation using figure-8 and deep H-coils. J Clin Neurophysiol 2007; 24(1): 31-8.
361. Leggio L, Kenna GA, Fenton M, et al. Typologies of alcohol dependence. From Jellinek to genetics and beyond. Neuropsychol Rev 2009; 19(1): 115-29.
362. Danysz W, Parsons CG, Jirgensons A, et al. Amino-alkylcyclohexanes as a novel class of uncompetitive NMDA receptor antagonists. Curr Pharm Des 2002; 8(10): 835-43.
363. Raaijmakers JA, Koster ES, Maitland-van der Zee AH. Pharmacogenetics and the pharmaceutical industry. Curr Pharm Des 2010; 16(2): 238-44.
364. Wang LL, Yang AK, He SM, et al. Identification of Molecular Targets Associated With Ethanol Toxicity and Implications in Drug Development. Curr Pharm Des 2010; 16(11): 1313-55.